Epimab Biotherapeutics

Bispecific antibody therapies using its proprietary FIT-Ig platform

placeShanghai, Shanghai, China calendar_todayFounded 2015 groups49 employees language epimab.com

Investor mix

16 investors on record; lead investors include SDIC Innovation, Sherpa Venture Capital, Yuanhe Holdings, CMB International Capital.

Investor typeCountShare
Venture capital850%
Private equity319%
Bank & private debt213%
Other / undisclosed319%
Coming soon